title: Doxazosin GITS versus standard doxazosin in mild to moderate hypertension.
abstract: BACKGROUND
  The selective alpha 1-adrenoceptor antagonist doxazosin in both standard formulation and gastrointestinal therapeutic system (GITS) controlled-release formulation is effective for hypertension without having a negative impact on serum lipids. This study was designed to compare the relative efficacy of these two formulations of doxazosin on clinic and ambulatory blood pressure and serum lipids in patients with mild to moderate hypertension.
  
  
  METHODS
  Hypertensive patients aged 18-70 years (n = 335) were evaluated in a multi-center prospective randomized study. Following a 2-week placebo run-in phase, patients were randomized to receive doxazosin 2 or 4 mg, with dose titration, or doxazosin GITS 4 mg, no dose titration, for 9 weeks.
  
  
  RESULTS
  Both doxazosin formulations reduced clinic diastolic and systolic blood pressure from baseline (P < 0.0001). Doxazosin GITS and doxazosin 4 mg had similar blood pressure-lowering effects. Doxazosin GITS reduced sitting diastolic and systolic blood pressure compared with doxazosin 2 mg (P < 0.01 for both). A greater proportion of the doxazosin GITS group reached goal blood pressure (< or = 140/90 mm Hg) after 9 weeks compared with the doxazosin 2-mg group. All doses of doxazosin reduced 24-h and daytime (7:00 am to 10:00 pm) ambulatory blood pressure from baseline (all P < 0.01). Doxazosin GITS significantly reduced nighttime (10:00 pm to 7:00 am) ambulatory blood pressure from baseline. A neutral effect on serum lipids was observed with doxazosin.
  
  
  CONCLUSIONS
  Doxazosin GITS and doxazosin were effective in reducing clinic and ambulatory blood pressure. The GITS formulation reduced the need for dose titration. Both doxazosin formulations were well tolerated.
authors.affiliation: Unidad de Hipertensión y Riesgo Vascular, Hospital Clínico Univeritario, Travesia de la Choupana s/n, 15706 Santiago de Compostela, Spain. igamevas@usc.es
authors.forename: Carlos
authors.initials: C
authors.lastname: Calvo
authors.forename: Blas
authors.initials: B
authors.lastname: Gil-Extremera
authors.forename: Pablo
authors.initials: P
authors.lastname: Gomez-Fernández
authors.forename: Xavier
authors.initials: X
authors.lastname: Masramon
authors.forename: Carol
authors.initials: C
authors.lastname: Pueyo
authors.forename: Beatriz
authors.initials: B
authors.lastname: Armada
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D018660:Blood Pressure Monitoring, Ambulatory; D003692:Delayed-Action Preparations; D017292:Doxazosin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D041981:Gastrointestinal Tract / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D008055:Lipids; D010919:Placebos; D017292:Doxazosin